Troy E. Wilson - Nov 13, 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Signature
Teresa Bair, Attorney-in-fact for Troy E. Wilson
Stock symbol
KURA
Transactions as of
Nov 13, 2025
Transactions value $
$0
Form type
4
Date filed
11/14/2025, 08:00 PM
Previous filing
Sep 29, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
WILSON TROY EDWARD President and CEO, Director C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO Teresa Bair, Attorney-in-fact for Troy E. Wilson 2025-11-14 0001589597

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +183K +73.93% $0.00 429K Nov 13, 2025 Direct F1
holding KURA Common Stock 279K Nov 13, 2025 by One Fish Two Fish Revocable Trust
holding KURA Common Stock 300K Nov 13, 2025 by Lorax Charitable Remainder Unitrust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 1/3rd of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.